Veloxis' Phase 3 Trial of LCP-Tacro in Stable Kidney Transplant Patients, the ... FierceDrugDelivery Non-inferiority was determined by a composite endpoint, measured over a year of follow up that included death, graft failure, biopsy-proven acute rejection or loss to follow-up. Results of this trial demonstrated that patients can be successfully ... |
